amcofen 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg
krka, d.d. - Мильбемицин оксим, Празиквантел - таблетка - 12.5 mg/таблетка, 125 mg/таблетка - кучета
milprazon chewable 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg
krka, d.d. - milbemycin oxime; praziquantel - таблетка - 12.5 mg; 125.0 mg/таблетка - кучета
milprazon chewable 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 mg
krka, d.d - Мильбемицин оксим, Празиквантел - таблетка - 2.5 mg; 25.9 mg/таблетка - кучета
milbeprazin 2.5 mg/25.0 mg
Фарма Вет ООД - milbemycin oxime; praziquantel - таблетка - 2.5 mg, 12.5 mg/таблетка; 25 mg, 125 mg/таблетка - кучета
alpramil 5 mg/50 mg таблетки за кучета с тегло най-малко 0,5 kg
alfasan nederland b.v. - milbemycin oxime; praziquantel - таблетка - 5.0 mg; 50.0 mg/таблетка - кучета
alpramil 12,5 mg/125 mg таблетки за кучета с тегло най-малко 5 kg
alf - milbemycin oxime; praziquantel - таблетка - 12.5 mg; 125.0 mg/таблетка - кучета
alpramil 20 mg/200 mg tablets for dogs weighing at least 8 kg/ alpramil 20 mg/200 mg таблетки за кучета с тегло най-малко 8 kg
alfasan nederland b.v. - Мильбемицин оксим, Празиквантел - таблетка - 20,0 mg, 200,0 mg/mg - кучета
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - Други противоэпилептические средства - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
blincyto
amgen europe b.v. - blinatumomab - Прекурсорна клетъчна лимфобластна левкемия-лимфом - Антинеопластични средства - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
bosulif
pfizer europe ma eeig - бозутиниб (като монохидрат) - Левкемия, миелоид - antineoplastic agents, protein kinase inhibitors - bosulif е показан за лечение на възрастни пациенти с идентифицирана за първи път хронична фаза (cp) на хромозомите-положителен Филаделфия хронична миелогенной левкемия (ph+ ХМЛ). СР, ускорена фаза (ap), и бластном (bp) ph+ ХМЛ, по-рано, на които един или повече инхибитори на тирозинкиназы(с) [tgc(И)] и за кого imatinib, nilotinib и dasatinib не се считат за подходящи възможности за лечение .